Current Search: ("mcudic@fau.edu") (x)
-
-
Title
-
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.
-
Creator
-
Lohmueller, Jason J., Sato, Shuji, Popova, Lana, Chu, Isabel M., Tucker, Meghan A., Barberena, Roberto, Innocenti, Gregory M., Cudic, Mare, Ham, James D., Cheung, Wan Cheung, Polakiewicz, Roberto D., Finn, Olivera J.
-
Abstract/Description
-
MUC1 is a shared tumor antigen expressed on >80% of human cancers. We completed the first prophylactic cancer vaccine clinical trial based on a non-viral antigen, MUC1, in healthy individuals at-risk for colon cancer. This trial provided a unique source of potentially effective and safe immunotherapeutic drugs, fully-human antibodies affinity-matured in a healthy host to a tumor antigen. We purified, cloned, and characterized 13 IgGs specific for several tumor-associated MUC1 epitopes with a...
Show moreMUC1 is a shared tumor antigen expressed on >80% of human cancers. We completed the first prophylactic cancer vaccine clinical trial based on a non-viral antigen, MUC1, in healthy individuals at-risk for colon cancer. This trial provided a unique source of potentially effective and safe immunotherapeutic drugs, fully-human antibodies affinity-matured in a healthy host to a tumor antigen. We purified, cloned, and characterized 13 IgGs specific for several tumor-associated MUC1 epitopes with a wide range of binding affinities. These antibodies bind hypoglycosylated MUC1 on human cancer cell lines and tumor tissues but show no reactivity against fully-glycosylated MUC1 on normal cells and tissues. We found that several antibodies activate complement-mediated cytotoxicity and that T cells carrying chimeric antigen receptors with the antibody variable regions kill MUC1+ target cells, express activation markers, and produce interferon gamma. Fully-human and tumor-specific, these antibodies are candidates for further testing and development as immunotherapeutic drugs.
Show less
-
Date Issued
-
2016-10-22
-
PURL
-
http://purl.flvc.org/fau/fd/FAUIR000012
-
Format
-
Citation
-
-
Title
-
Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
-
Creator
-
Mozdzanowska, Krystyna, Zharikova, Darya, Cudic, Mare, Otvos, Laszlo, Gerhard, Walter
-
Date Issued
-
2007-10-27
-
PURL
-
http://purl.flvc.org/fcla/dt/3327982
-
Format
-
Document (PDF)
-
-
Title
-
Engineered Sarafotoxins as Tissue Inhibitor of Metalloproteinases-like Matrix Metalloproteinase Inhibitors.
-
Creator
-
Lauer-Fields, Janelle L., Cudic, Mare, Wei, Shuo, Mari, Frank, Fields, Gregg B., Brew, Keith
-
Date Issued
-
2007-09
-
PURL
-
http://purl.flvc.org/fau/flvc_fau_islandoraimporter_10.1074_jbc.M611612200_1638212835
-
Format
-
Document (PDF)
-
-
Title
-
The Roles of Substrate Thermal Stability and P2 and P1′ Subsite Identity on Matrix Metalloproteinase Triple-helical Peptidase Activity and Collagen Specificity.
-
Creator
-
Minond, Dmitriy, Lauer-Fields, Janelle L., Cudic, Mare, Overall, Christopher M., Pei, Duanqing, Brew, Keith, Visse, Robert, Nagase, Hideaki, Fields, Gregg B.
-
Date Issued
-
2006-12
-
PURL
-
http://purl.flvc.org/fau/flvc_fau_islandoraimporter_10.1074_jbc.M606004200_1638203001
-
Format
-
Document (PDF)